CHICAGO — Commercial insurer payments for teprotumumab vary dramatically, with cost influencing access to care and cost-effectiveness, according to a study presented at the ASOPRS Fall Scientific Symposium.
Even though Tepezza (teprotumumab, Horizon Therapeutics) was found in the study to have the highest recorded measure of Graves’ orbitopathy quality of life (GO-QOL) compared with other thyroid eye disease (TED) treatments, it was also associated with the highest cost per unit of that change (GO-QOL), according to Tracy J. Lu, MD, of Stanford University School of Medicine.
“Our